Spark Therapeutics

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases.  The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver.  Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders.  Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration.  Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.

Avalara Inc

Guardant Health Inc

Iovance Biotherapeutics

Mirati Therapeutics

Roku

Sinclair Inc

Snap

Pfizer

Roku, Array Biopharma and Guardant Health are just some of the best stocks by returns for the first half of 2019. The post The 10 Best Stocks for 2019 — So Far appeared first on InvestorPlace.

The 10 Best Stocks for 2019 — So Far

Investors need to pay close attention to Spark Therapeutics (ONCE) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Spark Therapeutics (ONCE) Stock

Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Novartis

Invitae

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Roche said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

Roche says its $4.3 billion offer for Spark is still on track for June completion

Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.

Roche's 'Steep' Spark Buyout Could Put These Gene Therapy Names In Play

News for Spark Therapeutics Stock (ONCE)